Pipeline
ProStrakan's primary strength is in its multidisciplinary staff of about 30 professionals in R&D, trained throughout Europe and the United States, whose expertise covers all aspects of research and development. The development function is based at Galashiels in Scotland.
ProStrakan's R&D management has a significant track record with a broad spread of expertise including R&D, product development and approvals in both big pharma and biotech environments.
| Project |
Phase 1 |
Phase 2 |
Phase 3 |
Reg |
Launch |
Indication |
|---|---|---|---|---|---|---|
| Rectogesic EU |
Marketed |
Anal fissure pain | ||||
| Tostran EU |
Marketed | Male Hypogonadism | ||||
| Droperidol EU |
Marketed | Post-operative nausea and vomiting | ||||
| Abstral EU |
Marketed | Breakthrough cancer pain | ||||
| Sancuso EU |
In Reg. |
2010 |
Anti-emetic, cancer supportive care | |||
| Sancuso USA |
Marketed | Anti-emetic, cancer supportive care | ||||
| Abstral USA |
In Reg. |
2010 |
Breakthrough cancer pain | |||
| Cellegesic USA |
2010 |
Anal fissure pain | ||||
| FORTESTA USA |
In Reg. | 2010 |
Male Hypogonadism | |||
| Testosterone-glucoside (oral pro-drug) |
TBC |
Male Hypogonadism |

